Petrelli Fausto, Luciani Andrea, Borgonovo Karen, Ghilardi Mara, Parati Maria Chiara, Petrò Daniela, Lonati Veronica, Pesenti Angelo, Cabiddu Mary
Medical Sciences Department, Oncology Unit, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.
Clinical Diagnostics Department, Laboratory Medicine Unit, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.
J Med Virol. 2022 Jun;94(6):2837-2844. doi: 10.1002/jmv.27644. Epub 2022 Feb 12.
We analyzed published studies on the efficacy and safety of the third dose of the COVID-19 vaccine in various general population settings. We conducted systematic searches of PubMed and EMBASE for series published in the English language through November 15, 2021, using the search terms "third" or "booster" or "three" and "dose" and "COVID-19" or "SARS-CoV-2." All articles were selected according to the MOOSE guidelines. The seroconversion risk after third doses was descriptively expressed as a pooled rate ratio ([seroconversion rate after the third dose]/[seroconversion rate after the second dose]). The search returned 30 studies that included a total of 2 734 437 vaccinated subjects. In more than 2 700 000 Israeli patients extracted from the general population, the reduction in the risk of infection ranged from 88% to 92%. Conversion rates for IgG anti-spike ranged from 95% to 100%. In cancer or immunocompromised patients, mean IgG seroconversion was 39.4% before and 66.6% after third doses. A third dose seems necessary to protect against all COVID-19 infection, severe disease, and death risk.
我们分析了已发表的关于新冠疫苗第三剂在不同普通人群环境中的疗效和安全性的研究。我们在PubMed和EMBASE上进行了系统检索，以查找截至2021年11月15日以英文发表的系列研究，检索词为“第三剂”或“加强剂”或“三剂”以及“剂量”和“新冠病毒病”或“严重急性呼吸综合征冠状病毒2”。所有文章均根据MOOSE指南进行筛选。第三剂后的血清转化风险以合并率比（[第三剂后的血清转化率]/[第二剂后的血清转化率]）进行描述性表达。检索结果为30项研究，共纳入2734437名接种疫苗的受试者。在从普通人群中提取的超过270万名以色列患者中，感染风险降低幅度为88%至92%。IgG抗刺突蛋白的转化率为95%至100%。在癌症或免疫功能低下患者中，第三剂前IgG血清转化率平均为39.4%，第三剂后为66.6%。第三剂似乎对于预防所有新冠病毒感染、重症和死亡风险是必要的。
